NOV 02, 2015 12:58 PM PST

Gene Splicing Induces Resistance of B Cell Leukemia to Immunotherapy

WRITTEN BY: Kara Marker
B-cell leukemia occurs in 80-85 percent of children with acute lymphoblastic leukemia (ALL), a fast-growing cancer that can be treated with CD19 chimeric antigen receptor (CAR) T-cell immunotherapy, also known as CTL019. The treatment was developed by Carl June, MD, and his team from the University of Pennsylvania beginning in 2010. It works by removing T-cells from a patient's blood and genetically modifying them to target CD19 protein present on cancerous B cells (Children's Hospital of Philadelphia).
Pre-cursor B-cell Acute Lymphoblastic Leukemia
Although the American Association for Cancer Research (AACR) reports largely positive responses from B-cell leukemia patients receiving this therapy, the treatment fails in 10-20 percent of the patients, with only some capable of being retreated successfully.

Recent research published in Cancer Discovery revealed why cancer returns resistant to CTL019 in some patients and why the treatment fails initially in others. Scientists from the Children's Hospital of Philadelphia analyzed tumor samples from pediatric patients with aggressive leukemias and found splicing alterations in the gene coding for CD19. These mutations modified the protein to the point where it is no longer recognizable by T-cells during immunotherapy. 

Gene splicing can occur in different ways, and two can cause cancer cell resistance to treatment. When exons 5 and 6 are deleted, the protein terminates prematurely and is no longer capable of attaching to the cancer cell surface to be recognized by T-cells. When exon 2 is deleted, CD19 protein is seen on the cell surface, but the modified protein is no longer targetable by treatment. 

This discovery will prompt scientists to individualize treatment and direct targets toward the mutated proteins. Plus, Andrei Thomas-Tikhonenko, PhD, and senior scientist from his lab, says the "CD19 genetic code was not irretrievably lost," hinting that there might be a way to resurrect the original protein to be targeted by immunotherapy. Thomas-Tikhonenko and team are also considering targeting other proteins present in cancer cells that are not commonly spliced as a mechanism of resistance, to avoid the troubling phenomenon all together. Ultimately, this discovery will lead to better treatment of B-cell leukemia based on individual cases of the cancer. 

Watch the following video to learn more about CTL019 and how it is used to treat other cancers like B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
 

Source: American Association for Cancer Research 

 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 08, 2018
Immunology
OCT 08, 2018
Natural Killer Cells to Aid in Cancer Therapy
Researchers utilize nanoparticles to stimulate NK cells that induce tumor cells to express PDL1, a protein involved in immune response messaging...
OCT 21, 2018
Immunology
OCT 21, 2018
B -cells Drive auto-T-cells to the Brain
Researchers have provided a paradigm shift in the understanding of auto-reactive T cells in the brain of Multiple Sclerosis patients....
DEC 04, 2018
Immunology
DEC 04, 2018
Shared Bacteria After Birth
A study reveals the benefits of natural birth over cesarean birth in regards to immune development...
DEC 20, 2018
Health & Medicine
DEC 20, 2018
Common Medication Regimens for Sarcoidosis
Sarcoidosis is a granulomatous disease that most commonly affects the lungs, but any organ system can be involved. It is most often found and diagnosed in...
JAN 09, 2019
Immunology
JAN 09, 2019
What We Don't Know Won't Hurt Us, Right?
A review in Frontiers in Pediatrics describes a common food additive that could both create and trigger autoimmune attacks, calling for warnings on food labels pending further tests....
JAN 15, 2019
Immunology
JAN 15, 2019
A Possible Key to Severe Flu
By studying the impact that NPY and its receptor Y1R have on influenza in mice, the research group has now discovered that NPY produced in lung phagocytes can aggravate influenza....
Loading Comments...